SEC Company Response from 4D Molecular Therapeutics, (FDMT) — Sep 1, 2022
4D Molecular Therapeutics, Inc.
Date: Sept. 1, 2022 · CIK: 0001650648 · Accession: 0001193125-22-236564
AI Filing Summary & Sentiment
File numbers found in text: 333-267013
Letter
4D Molecular Therapeutics, Inc.
5858 Horton Street, #455
Emeryville, California 94608
September 1,
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Dillon Hagius
Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-267013)
To the addressee set forth above:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-3 (Registration No. 333-267013) (the “Registration Statement”) of 4D Molecular Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 6, 2022, or as soon as practicable thereafter, or at such other time thereafter as our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or Phillip Stoup at (415) 395-8216.
Thank you for your assistance in this matter.
Very truly yours,
4D MOLECULAR THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
4D Molecular Therapeutics, Inc.
5858 Horton Street, #455
Emeryville, California 94608
September 1,
2022
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of
Corporation Finance
Office of Life Sciences
100 F Street,
N.E.
Washington, D.C. 20549-6010
Attention:
Dillon Hagius
Re: 4D Molecular Therapeutics, Inc. Registration Statement on Form S-3 (Registration No. 333-267013)
To the addressee set forth above:
In accordance with Rule 461 under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the
Registration Statement on Form S-3 (Registration No. 333-267013) (the “Registration Statement”) of 4D Molecular Therapeutics, Inc. (the
“Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 6, 2022, or as soon as practicable thereafter, or at such other time thereafter as
our counsel, Latham & Watkins LLP may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Mark Roeder at (650) 463-3043 or Phillip Stoup at (415) 395-8216.
Thank you for your
assistance in this matter.
Very truly yours,
4D MOLECULAR THERAPEUTICS, INC.
By:
/s/ August Moretti
August Moretti
Chief Financial Officer
cc:
David Kirn, M.D., 4D Molecular Therapeutics, Inc.
Scott Bizily, J.D., Ph.D., 4D Molecular Therapeutics, Inc.
Mark V. Roeder, Latham & Watkins LLP
Phillip S. Stoup, Latham & Watkins LLP